An Amyloid Monopoly? Did a Scientific "Mafia" Stifle Alzheimer’s Research? Betting on the Wrong Alzheimer’s Horse?

Investigative journalist Charles Piller, writing for STAT and Science, exposes what he cites as deep flaws in the amyloid hypothesis of Alzheimer’s disease and the entrenched power structure that has suppressed alternative research for decades. The article critiques the dominance of the "amyloid mafia"—a powerful network of researchers, pharmaceutical companies, and advocacy groups that have aggressively pushed amyloid-targeting therapies (ATTs) despite mounting evidence of their limited efficacy and severe risks.

The Amyloid Controversy